PRKG2 encodes cGMP-dependent protein kinase II (cGKII), a serine/threonine kinase that serves as a crucial regulator of bone growth and intestinal secretion 1. The kinase is prominently expressed in secretory epithelium of the small intestine, juxtaglomerular cells, adrenal cortex, and chondrocytes 2. PRKG2 functions as a major downstream effector in the NO/cGMP and ANP/cGMP signaling pathways, specifically inhibiting renin secretion, chloride/water secretion in the small intestine, and regulating endochondral bone growth 1. In chondrogenic differentiation, PRKG2 acts downstream of the CNP/NPR-B/cGMP pathway, phosphorylating c-Raf 1 at Ser43 and subsequently activating ERK1/2 signaling in response to growth factors 3. Loss-of-function mutations in PRKG2 cause acromesomelic dysplasia, characterized by severe short stature, limb shortening, and disrupted endochondral ossification 3. Similar skeletal dysplasias have been documented in Dalmatian dogs carrying PRKG2 nonsense mutations 4. Additionally, PRKG2 polymorphisms have been associated with gout susceptibility in some populations 5 and vertebral traits in livestock 6. Notably, PRKG2 fusion proteins with PDGFRB have been identified in atypical myeloproliferative disorders, which respond to imatinib therapy 7.